Blenrep (Belantamab mafodotin) combinations approved in Canada for the treatment of relapsed/refractory multiple myeloma

CAR-T Digest - August 2020

23 July 2025: Blenrep (Belantamab mafodotin) combinations approved in Canada for the treatment of relapsed/refractory multiple myeloma

Health Canada approved GSK’s Blenrep in combination with Bortezomib + Dexamethasone or Pomalidomide + Dexamethasone for adults with relapsed/refractory multiple myeloma after at least one prior therapy
This decision is backed by impressive results from the Phase 3 DREAMM-7 and DREAMM-8 trials, where Blenrep combinations showed significantly better outcomes in terms of progression-free and overall survival compared to standard treatments
Blenrep now becomes the first and only anti-BCMA antibody-drug conjugate approved in Canada for multiple myeloma. It brings a novel mechanism of action and offers the convenience of outpatient administration, no need for hospital stays
The drug demonstrated consistent benefits across patient subgroups, including those with high-risk cytogenetics or refractory to lenalidomide, with deeper and more durable responses than comparators